84.18
-1.02 (-1.20%)
| Penutupan Terdahulu | 85.20 |
| Buka | 85.81 |
| Jumlah Dagangan | 329,637 |
| Purata Dagangan (3B) | 834,852 |
| Modal Pasaran | 5,748,234,752 |
| Harga / Jualan (P/S) | 29.38 |
| Harga / Buku (P/B) | 42.13 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| Margin Keuntungan | -123.28% |
| Margin Operasi (TTM) | -143.73% |
| EPS Cair (TTM) | -2.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 25.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 69.65% |
| Nisbah Semasa (MRQ) | 3.30 |
| Aliran Tunai Operasi (OCF TTM) | -113.49 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -96.71 M |
| Pulangan Atas Aset (ROA TTM) | -51.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -150.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Rhythm Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.88 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.65% |
| % Dimiliki oleh Institusi | 103.78% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 176.00 (Citizens, 109.08%) | Beli |
| Median | 143.00 (69.87%) | |
| Rendah | 110.00 (HC Wainwright & Co., 30.67%) | Beli |
| Purata | 142.29 (69.03%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 95.39 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 12 Mar 2026 | 143.00 (69.87%) | Beli | 91.15 |
| 27 Feb 2026 | 136.00 (61.56%) | Beli | 92.73 | |
| Canaccord Genuity | 02 Mar 2026 | 140.00 (66.31%) | Beli | 94.94 |
| HC Wainwright & Co. | 02 Mar 2026 | 110.00 (30.67%) | Beli | 94.94 |
| Citizens | 27 Feb 2026 | 176.00 (109.08%) | Beli | 92.73 |
| Guggenheim | 27 Feb 2026 | 143.00 (69.87%) | Beli | 92.73 |
| Needham | 26 Feb 2026 | 139.00 (65.12%) | Beli | 98.07 |
| RBC Capital | 19 Feb 2026 | 145.00 (72.25%) | Beli | 103.16 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |